Causal relationships between plasma proteins and Alzheimer's disease using bidirectional Mendelian randomization
Yichen Li1,2, Yu-Lin Yao3, Yong Wu1,2
1Department of Psychiatry, Wuhan Mental Health Center, Wuhan, Hubei, China.
This study used Mendelian randomization to identify 25 plasma proteins causally linked to Alzheimer's disease (AD), highlighting roles for immune and lipid pathways in AD pathogenesis.
Area of Science:
- Neuroscience
- Genetics
- Biochemistry
Background:
- Alzheimer's disease (AD) pathogenesis involves complex genetic, immune, and metabolic interactions.
- Identifying causal plasma proteins can elucidate AD pathways and reveal therapeutic targets.
Purpose of the Study:
- To investigate causal relationships between Alzheimer's disease (AD) and plasma protein levels.
- To explore both forward (protein to AD) and reverse (AD to protein) causal effects.
Main Methods:
- A two-stage, two-sample Mendelian randomization (MR) analysis was performed.
- Genome-wide association study datasets for plasma proteins and AD were utilized.
- Non-overlapping datasets ensured robust and independent analyses.
Main Results:
- Twenty-five plasma proteins demonstrated causal associations with Alzheimer's disease (AD).
- Many identified proteins are involved in immune and lipid metabolic pathways.
- Findings support the role of inflammation and lipid metabolism in AD.
Conclusions:
- This research strengthens the link between immune and lipid dysregulation in AD.
- Identified proteins may serve as novel biomarkers or therapeutic targets for AD.
- Advances understanding of molecular mechanisms in AD progression.
More Related Videos
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer's Disease: Treatment
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
